Notification of Preliminary Results (8684D)
March 30 2011 - 2:01AM
UK Regulatory
TIDMIMM
RNS Number : 8684D
Immupharma PLC
30 March 2011
For Immediate Release 30 March 2011
ImmuPharma PLC
Notification of Preliminary Results
Date : 5 April 2011
ImmuPharma PLC (AIM:IMM), the specialist discovery and
development pharmaceutical company, is scheduled to announce its
Preliminary Results for the year ended 31 December 2010 on 5 April
2011.
An analyst meeting will be held at 10.00am on the day of the
results. A webcast will run simultaneously to the meeting and will
be available via the following link:
http://mediaserve.buchanan.uk.com/2011/immupharma050411/registration.asp
- Ends -
For further information, please contact:
ImmuPharma PLC:
Dr Robert Zimmer, President & Chief Scientific Officer + 33
389 32 76 50
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Buchanan Communications
Lisa Baderoon
Mark Court +44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett
Rakesh Sharma +44 20 7459 3600
Espirito Santo Investment Bank
James Bromhead
Richard Crawley +44 20 7456 9191
Notes to Editors:
About ImmuPharma
ImmuPharma PLC is a drug discovery and development company
headquartered in London, UK and quoted on AIM of the London Stock
Exchange (LSE:IMM). It has research operations in France
(ImmuPharma (France) SA) and Switzerland (ImmuPharma AG).
ImmuPharma is dedicated to the development of novel drugs, largely
based on peptide therapeutics, to treat serious medical conditions
such as autoimmune diseases characterised by:
-- blockbuster potential in niche markets
-- low promotional costs in few specialised physicians and
centres and
-- lower risk of drug development and lower development
costs
ImmuPharma is a currently developing drug candidates for three
different medical conditions, each of which would represent a
significant breakthrough in its field. The furthest advanced drug
candidate targets Lupus, a disease for which there is currently no
cure or specific treatment. The other two address moderate to
severe pain (such as that experienced by cancer sufferers and
post-operative patients), and MRSA and similar severe
hospital-acquired resistant infections.
All three have significant sales potential as well as low
marketing costs and a relatively low risk of development failure.
One or more have the potential to be fast-tracked by the US Food
and Drug Administration according to "Guidance for Industry: Fast
Track Drug Development Programs - Designation, Development and
Application Review" issued July 2004 and could therefore obtain
their market authorization by 2010.
Key to the potential success of ImmuPharma is its unique
collaborative agreement with Centre National de la Recherche
Scientifique, France's scientific research institution. This
agreement grants ImmuPharma worldwide exclusive rights to exploit
certain key discoveries.
In addition to its three leading drug candidates, ImmuPharma has
a drug development pipeline using its rights to a virtual chemical
library of hundreds of thousands of molecules as well as an
innovative technology for converting peptides to drug
candidates.
ImmuPharma has the option to commercialise its assets itself or
to license them to other pharmaceutical companies at an earlier
stage.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREAXDNAANFEFF
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024